The Endocannabinoid System: The Body’s Cannabis Receptor Network

Last updated on September 13, 2026 · Originally published November 20, 2018

Many of cannabis’s best-known effects – the high, appetite changes, pain modulation, and memory impairment – begin with one biological system. It is called the endocannabinoid system, and the strangest thing about it is the order of discovery: science found the plant’s key first, and only then went looking for the lock.

This article is the plain-language map: what the system is, what it does all day when no cannabis is involved, how the plant’s compounds plug into it, and – because this is the most over-hyped topic in cannabis writing – an honest accounting of what it does and doesn’t explain.

What is the endocannabinoid system?

Three parts: receptors, the body’s own signalling molecules, and the enzymes that clean up after them.

The receptors. In 1988, researchers found a specific binding site for THC in rat brains – proof that the body had dedicated machinery this plant compound fit into [1]. In 1990, that machinery was cloned and named the cannabinoid type 1 receptor, CB1 [2]. It turned out to be one of the most abundant receptors of its kind in the brain, and it also shows up in the liver, gut, pancreas, fat, and muscle. In 1993 came a second receptor, CB2, present mainly on immune cells – including brain immune cells, whose CB2 expression can increase during inflammation [3,13].

The body’s own cannabinoids. Receptors don’t exist to wait for a plant. So the next question was obvious: what does the body make that these receptors are for? In 1992, Raphael Mechoulam’s lab isolated the first answer – a small fatty molecule they named anandamide, from the Sanskrit ananda, bliss [4]. In 1995, two labs independently identified a second, 2-arachidonoylglycerol – mercifully shortened to 2-AG – which turns out to be the workhorse, present in mammalian brain tissue at concentrations roughly a hundred times higher than anandamide [5,6]. These are the endocannabinoids: endo for endogenous, made in-house.

The cleanup enzymes. Endocannabinoids are made on demand and destroyed on schedule. An enzyme called FAAH breaks down anandamide [7]; an enzyme called MAGL clears 2-AG – characterized in the lab of Daniele Piomelli, one of the founding scientists of the field whom we interviewed about the system he helped map [8]. The enzymes matter because they set the signal’s length: a message that is erased quickly can be sent precisely.

That is the simplified core: two recognised cannabinoid receptors, two main messengers, and their principal cleanup enzymes. The full system includes additional enzymes and molecular targets, but CB1, CB2, anandamide, and 2-AG remain its best-mapped components.

What does the ECS actually do?

The original version of this article called homeostasis “a silent vigilante, working behind the scenes to maintain order” – and that framing has aged well, so it stays. Homeostasis is the body’s constant, unglamorous work of keeping internal conditions within workable ranges as circumstances change – temperature, energy availability, and inflammatory activity among them.

The ECS is one of several systems involved in that regulation, particularly in neural activity, appetite, pain processing, stress responses, metabolism, and immune signalling – and the way it works is genuinely unusual. Most neural signals travel forward, from the talking neuron to the listening one. Endocannabinoids travel backward. When a neuron is being stimulated hard, it can synthesize endocannabinoids on the spot and release them back at the neuron doing the talking, where CB1 receptors act like a volume knob and turn the incoming signal down [9].

That is one of the system’s characteristic jobs: short-range feedback on synaptic signalling. At many synapses, CB1 acts like a temporary volume control on neurotransmitter release. But the signal being reduced may be excitatory or inhibitory – and turning down an inhibitory signal can make a circuit more active – so the ECS does not simply calm the brain down. It tunes particular circuits according to what is happening locally.

The brain example is not the entire system, either. Outside synapses, endocannabinoid signalling also helps regulate immune activity, gut function, and energy metabolism. These signals are produced and controlled locally; there is no single body-wide ECS level that can simply be “low” or restored to “balance.” That broad distribution helps explain why the receptor map reads like a list of things cannabis famously affects – appetite circuits, pain pathways, memory centres, and immune cells. The plant did not create that regulatory machinery. It found it already installed.

Image credit: modified from Homeostasis: Figure 1 by OpenStax College, Anatomy & Physiology, CC BY 4.0

How does cannabis interact with it?

The best-known cannabinoids interact with this system in very different ways – and those differences explain much of what users notice.

THC is an anandamide impersonator without anandamide’s precise timing. THC partially activates CB1 and CB2 receptors [10] – but where anandamide is produced locally and cleared rapidly, THC reaches receptors across the brain and body and can influence them for hours. A precisely timed local message becomes something closer to a building-wide announcement. That helps produce the high, appetite changes, and memory impairment: familiar circuits operating outside their normal timing and balance. The finer points of how THC’s molecular shape determines this fit – and what happens in its delta-8 and delta-10 cousins – come down to CB1 receptor mechanics.

CBD barely touches CB1 or CB2 directly. It does not strongly activate either receptor – which is why it doesn’t intoxicate – and works through several indirect routes that are still being mapped. CBD treatment has been associated with increased anandamide levels in one human study [11], but exactly how reliably it alters endocannabinoid signalling – and how much that explains its effects – remains unsettled. The honest summary is that CBD interacts with the endocannabinoid system without doing what THC does to it.

Some compounds are stranger. THCV can antagonise CB1 at low concentrations and behave as an agonist at higher doses in experimental models [10] – a split personality our THCV article covers, and the reason it keeps being studied for appetite. And one compound that binds CB2 directly isn’t a cannabinoid at all by the usual definition: β-caryophyllene, a terpene found in black pepper as well as cannabis, a genuine dietary cannabinoid – the term comes from the study that demonstrated its direct CB2 binding [12]. Whether cannabis compounds meaningfully modify each other’s effects at these receptors is its own contested question – our entourage-effect review keeps that scoreboard.

What does the ECS explain – and what doesn’t it?

Here is where this article corrects its own past. An earlier version of this page warned that when homeostasis fails, “all hell breaks loose,” and listed arthritis, epilepsy, strokes, obesity, Alzheimer’s, glaucoma, and cancer. That list is the standard move in cannabis writing – and it smuggles in a claim the evidence doesn’t make.

What the ECS genuinely explains is much of why the best-known cannabinoids do what they do: why one plant affects appetite and pain and memory and mood at once (because its receptors sit in all those circuits), why THC intoxicates and CBD doesn’t (different receptor behavior), why effects are dose-dependent and body-wide. That is a real and satisfying explanation, and four decades ago nobody had it.

What it does not establish: that diseases are caused by ECS imbalance, that cannabis “restores balance,” or that a system involved in everything can treat everything. Involvement is not causation, and a receptor’s presence in a diseased tissue is not a prescription. Even “clinical endocannabinoid deficiency” – the proposal that some conditions stem from low endocannabinoid tone – remains a hypothesis under investigation, not a diagnosis. The pharmaceutical record enforces the same humility: drugs targeting this system have produced both real medicines and instructive failures, a history our article on targeting the ECS in pharmacotherapy walks through.

The ECS is not a magic balance dial. It is something better: a real, mapped, druggable signalling system – the reason cannabis pharmacology is science rather than folklore.

Where to go deeper

This page is the trunk of our endocannabinoid coverage; the branches are worth your time. For the discovery story told properly, read how the endocannabinoids got their origin story. For the neuroscience of that backward-traveling signal, endocannabinoid signalling in the brain goes a level deeper. And for the view from the summit, our conversation with Dr. Daniele Piomelli – one of the founders of the field – lets you hear this science from someone who helped discover it.

References

1. Devane WA, Dysarz FA III, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 1988;34(5):605-613.
2. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564. doi:10.1038/346561a0
3. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65. doi:10.1038/365061a0
4. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
5. Mechoulam R, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 1995;50:83-90.
6. Sugiura T, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochemical and Biophysical Research Communications. 1995;215:89-97.
7. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 1996;384:83-87.
8. Dinh TP, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. PNAS. 2002;99:10819-10824.
9. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience. 2003;4:873-884.
10. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology. 2008;153:199-215.
11. Leweke FM, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry. 2012;2:e94.
12. Gertsch J, et al. Beta-caryophyllene is a dietary cannabinoid. PNAS. 2008;105(26):9099-9104. doi:10.1073/pnas.0803601105
13. Atwood BK, Mackie K. CB2: a cannabinoid receptor with an identity crisis. British Journal of Pharmacology. 2010;160:467-479.

Last updated September 13, 2026 – rebuilt and expanded, merging our earlier Homeostasis and ECS Simplified articles into this page · Originally published November 20, 2018 · Scientifically reviewed by Chana Frenkel, Ph.D. · Edited by Nani Frenkel, chief editor.